Mochida Of Japan Looks To Double Generic Output In Three Years (Japan)
This article was originally published in PharmAsia News
Mochida Pharmaceutical of Japan plans to concentrate on developing its own drugs and buying marketing rights from other companies as part of an overall plan to more than double its generic output within three years. Mochida is looking to produce 20 to 30 drugs during that period while holding down research and development expenses. Most of the new drugs are keyed to its strong position in cardiology, obstetrics, dermatology and emergency care. Mochida also plans to create products with added value. (Click here for more - may require a subscription
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.